Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection
Status:
Recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
Treatment of regionally-advanced head and neck squamous cell carcinoma (HNSCC) requires a
multidisciplinary approach with a combination of surgery, radiotherapy (RT) and chemotherapy.
Due to these aggressive combined modalities, patients undergoing treatment and many survivors
develop toxicities which impact quality of life (QoL) and sometimes lead to mortality.
Lymph node metastases of HNSCC are frequent and considered one of the most important
prognostic factors, resulting in decreased survival by 50%. More than three decades, the
optimal management strategy of node positive HNSCC was a key subject of debate. In summary,
the current literature provides us two important findings: First, with the contemporary
imaging and treatment modalities, there is no role of a planned neck dissection (ND) added to
(chemo)radiotherapy ((C)RT) in terms of oncological outcome and survival. Second, with modern
RT techniques, a tailored treatment followed after an up-front neck dissection (UFND) allows
a significant reduction of treatment volumes and de-escalation of the dose to the neck,
leading to reduction of treatment related toxicities.
In this study strategies with and without up-front neck dissection prior to
chemo-radiotherapy will be compared.